<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299923</url>
  </required_header>
  <id_info>
    <org_study_id>ML 18545 (TRELA)</org_study_id>
    <secondary_id>EudraCT-Nr.: 2005-001207-19</secondary_id>
    <nct_id>NCT00299923</nct_id>
  </id_info>
  <brief_title>Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy</brief_title>
  <official_title>Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hamburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <brief_summary>
    <textblock>
      The aim of this study is, to compare the relapse rate in chronic HCV patients with genotype 1
      or 3 under the combination of standard dose Peg-Interferon alfa-2a (PEG-IFN alfa-2a),
      Ribavirin (RBV) and Amantadine (AMA) given for 72 weeks (group A), versus the same
      combination, given for 48 weeks (group B) in patients who relapsed to previous combination
      therapy to conventional or pegylated (PEG) Interferon alfa and Ribavirin. Relapse ist defined
      as percentage of patients with non-detectable HCV-RNA at end of therapy (week 48 GT1/ week 24
      GT 3) who become HCV-RNA positive during a follow-up period of 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Comparison of the rate of relapse under the combination of standard dose PegIFN alfa-2a, Ribavirin and Amantadine given for 72 vs. 48 weeks.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>relationship between EVR during the first twelve weeks and SVR</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virological response to the combination of standard dose defined as reduction of HCV RNA at week 4, 12, 24, 48 and 72 of treatment, separated between HCV-Genotypes.</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Relapse</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a, Ribavirin, Amantadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsers to previous combination therapy with (PEG-)IFN alfa-/Ribavirin and a
             negative HCV-RNA test result at the end of this regular treatment course and positive
             HCV-RNA test result during the follow-up period.

          -  Termination of (PEG-)IFN alfa-/ribavirin therapy at least 3 months prior to enrolment

          -  Chronic HCV infection genotype 1 or 3.

          -  Serum HCV-RNA quantifiable at &gt;100 IU/mL by COBAS AmpliPrep or another quantitative
             HCV-RNA PCR test (reported in IU)

          -  Compensated liver disease (Child-Pugh A)

          -  Exclusion of HCC in patients with cirrhosis or transition to cirrhosis. In patients
             with AFP &gt;50 ng/mL an established assay for exclusion of HCC has to be done

          -  Negative urine or blood pregnancy test

          -  All fertile males and females must use two reliable forms of effective contraception
             (combined) during treatment with study drugs and 6 months post treatment

        Exclusion Criteria (at screening):

          -  Hypersensitiveness to Interferon, PEG-IFN alfa-2a, Ribavirin and Amantadine or other
             ingredient of the drugs

          -  Ongoing pregnancy or breast feeding

          -  Male partners of women who are pregnant or with women without effective contraception

          -  Signs or symptoms of hepatocellular carcinoma

          -  Chronic HCV infection genotype 2, 4, 5 or 6

          -  Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment &lt;
             6 months prior to the first dose of study drug and during study period. Exception:
             patients who have had a limited (&lt; 7 days) course of acyclovir or valacyclovir for
             herpetic lesions &lt; 1 month prior to the first administration of test drug are not
             excluded.

          -  Any investigational drug &lt; 6 weeks prior to the first dose of study drug

          -  Positive test for anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HIV

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HCV

          -  History or other evidence of decompensated liver disease or a Child-Pugh score &gt; 6.

          -  Hb &lt;12 g/dL (&lt;120 g/L) in women or &lt;13 g/dL (&lt;130 g/L) in men at screening

          -  Any patient with an increased baseline risk for anemia or for whom anemia would be
             medically problematic

          -  Neutrophil count &lt;1,500 cells/mm3 and/or platelet count &lt;90,000 cells/mm3

          -  Serum creatinin concentration &gt;1.5 mg/dl

          -  History of severe psychiatric disease, especially depression.

          -  History of a severe seizure disorder that can not be stabilized by medication

          -  History of immunologically mediated disease

          -  Chronic pulmonary disease associated with functional limitation

          -  History of severe cardiac disease

          -  History of major organ transplantation except corneatransplantation

          -  Evidence of severe illness, malignancy, or any other conditions which would make the
             patient, in the opinion of the investigator, unsuitable for the study

          -  Thyroid dysfunction not adequately controlled

          -  Evidence of severe retinopathy or clinically relevant ophthalmological disorder due to
             diabetes mellitus or hypertension

          -  Evidence of active drug abuse within one year of study entry except of a prescribed
             stable opioid substitution

          -  Take of Memantine during study period

          -  Cardiomyopathy and myocarditis

          -  AV-Block II° and III°

          -  Pre-existing bradycardia &lt; 55 counts/min

          -  Known QT-interval (QTc after Bazett &gt; 420 ms) or recognized U-waves or congenital
             QT-syndrome

          -  History of severe ventricular arrhythmia incl. Torsade de pointes

          -  Simultaneous therapy with Budipin or other medicine that extend the QT-interval like
             (e.g.antiarrhythmic drugs class IA and class III, antipsychotic drugs, tri- and
             tetracyclic antidepressants, antihistaminics, macrolide, gyrase inhibitors,
             Azol-antimykotics)

          -  Patients with obstructive glaucoma

          -  Patients with excitableness and confusion

          -  Patients with delirium and exogenic psychosis in the anamnesis

          -  Prostataadenome

          -  Diuretic medication of the type combination Triamterene/ Hydrochlorothiazide

          -  Inability or unwillingness to provide informed consent or abide by the requirements of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Buggisch, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik 1</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Würtemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württembeg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. W.-Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruhr-Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Josef-Hospital</name>
      <address>
        <city>Oberhausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>46045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Bad Homburg/ Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Medizinischen Fakultät der Martin-Luther Universität Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Möller/ Heyne</name>
      <address>
        <city>Berlin</city>
        <zip>10696</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow-Klinikum, Med. Klinik (Gastroenterologie/ Hepatologie)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Med. Klinik 1</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2006</study_first_posted>
  <last_update_submitted>March 8, 2007</last_update_submitted>
  <last_update_submitted_qc>March 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2007</last_update_posted>
  <keyword>drug therapy</keyword>
  <keyword>Interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

